UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

7000 ORAL Final Overall Survival (OS) Analysis of COU-AA-301, a Phase 3 Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Pretreated With Docetaxel

European journal of cancer (1990), 2011, Vol.47, p.S483-S484

2011

Volltextzugriff (PDF)

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma

Annals of oncology, 2012-01, Vol.23 (1), p.46-52

2012

Volltextzugriff (PDF)

Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from ‘castration-resistant’ prostate cancer

Annals of oncology, 2017-08, Vol.28 (8), p.1692-1694

2017

Volltextzugriff (PDF)

Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial

Annals of oncology, 2012-03, Vol.23 (3), p.688-694

2012

Volltextzugriff (PDF)

The role of caveolin-1 in prostate cancer: clinical implications

Prostate cancer and prostatic diseases, 2010-03, Vol.13 (1), p.6-11

2010

Volltextzugriff (PDF)

High-Definition Single Cell Analysis (Hd-Sca) of Prostate Cancer (Pca) Cells in Matched Bone Marrow and Blood from Patients

Annals of oncology, 2014-09, Vol.25, p.iv268

2014

Volltextzugriff (PDF)

777PHIGH-DEFINITION SINGLE CELL ANALYSIS (HD-SCA) OF PROSTATE CANCER (PCA) CELLS IN MATCHED BONE MARROW AND BLOOD FROM PATIENTS

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv268-iv268

2014

Volltextzugriff (PDF)

7028 Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer (CRPC): analysis of Study CA180–086

European journal of cancer supplements, 2009, Vol.7 (2), p.415-415

2009

Volltextzugriff (PDF)

1053PDFINITE ANDROGEN DEPRIVATION THERAPY (ADT) PLUS IPILIMUMAB (IPI) IN MEN WITH HORMONE-NAïVE METASTATIC PROSTATE CANCER (HN-MPCA)

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv363-iv363

2014

Volltextzugriff (PDF)

Finite Androgen Deprivation Therapy (Adt) Plus Ipilimumab (Ipi) in Men with Hormone-Naïve Metastatic Prostate Cancer (Hn-Mpca)

Annals of oncology, 2014-09, Vol.25, p.iv363

2014

Volltextzugriff (PDF)

Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer

Prostate cancer and prostatic diseases, 2015-09, Vol.18 (3), p.276-280

2015

Volltextzugriff (PDF)

Usefulness of the top-scoring pairs of genes for prediction of prostate cancer progression

Prostate cancer and prostatic diseases, 2010-09, Vol.13 (3), p.252-259

2010

Volltextzugriff (PDF)

4025 POSTER A phase I/II study of sunitinib in combination with docetaxel (dcx) and prednisone (pdn) in patients with metastatic castrate-resistant prostate cancer (mCRPC)

European journal of cancer supplements, 2007, Vol.5 (4), p.287-287

2007

Volltextzugriff (PDF)

A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation

Oncogene, 2008-09, Vol.27 (39), p.5195-5203

2008

Volltextzugriff (PDF)

The Impact of Abiraterone Acetate (AA) Therapy on Patient-Reported Pain and Functional Status in Chemotherapy-Naive Patients with Progressive, Metastatic Castration-Resistant Prostate Cancer (MCRPC)

Annals of oncology, 2012-09, Vol.23, p.ix295

2012

Volltextzugriff (PDF)

556 Abiraterone acetate improves overall survival in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Impact of crossover and baseline prognostic factors in the COU-AA-302 final analysis

European urology supplements : official journal of the European Association of Urology, 2015-04, Vol.14 (2), p.e556-e556a

2015

Volltextzugriff (PDF)

97 Updated interim analysis (IA): Results of randomized phase 3 study COU-AA-302 of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy

European urology supplements : official journal of the European Association of Urology, 2013-03, Vol.12 (1), p.e97-e98

2013

Volltextzugriff (PDF)

625 THE SPECIFIC CLINICAL CHARACTERISTICS OF DUCTAL PROSTATE CANCER

European urology supplements : official journal of the European Association of Urology, 2009-03, Vol.8 (4), p.277-277

2009

Volltextzugriff (PDF)

Obesity, Weight Gain, and Risk of Biochemical Failure Among Prostate Cancer Patients Following Prostatectomy

The Journal of urology, 2006-04, Vol.175 (4), p.1365-1366

2006

Volltextzugriff (PDF)

Germ-cell tumor survivors: the price for cure

Annals of oncology, 2002-02, Vol.13 (2), p.187-189

2002

Volltextzugriff (PDF)

ACTIVE SURVEILLANCE FOR CLINICALLY LOCALIZED PROSTATE CANCER IN THE ERA OF TECHNOLOGY: INTRODUCTION OF A PROSPECTIVE PROTOCOL INTO A HIGH VOLUME TERTIARY REFERRAL CENTRE

European urology supplements : official journal of the European Association of Urology, 2008, Vol.7 (3), p.234-234

2008

Volltextzugriff (PDF)

A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final resultsof a phase III randomized trial

Annals of oncology, 2002-01, Vol.13 (1), p.125-136

2002

Volltextzugriff (PDF)

Pattern of Failure and Survival of Patients with Metastatic Urothelial Tumors Relapsing after Cis-Platinum-Based Chemotherapy

The Journal of urology, 1994-03, Vol.151 (3), p.598-600

1994

Volltextzugriff (PDF)

79 POSTER Correlative results of in-vivo monitoring of platelet-derived growth factor receptor (PDGFR) activation status in a randomized placebocontrolled trial of docetaxel +/− imatinib in castration-resistant prostate cancer (CRPC) and bone metastases (BM)

European journal of cancer supplements, 2006-11, Vol.4 (12), p.28-28

2006

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(33)
Buchkapitel
(1)

Sprache

Englisch
(34)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

7000 ORAL Final Overall Survival (OS) Analysis of COU-AA-301, a Phase 3 Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Pretreated With Docetaxel

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from ‘castration-resistant’ prostate cancer

Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial

The role of caveolin-1 in prostate cancer: clinical implications

High-Definition Single Cell Analysis (Hd-Sca) of Prostate Cancer (Pca) Cells in Matched Bone Marrow and Blood from Patients

777PHIGH-DEFINITION SINGLE CELL ANALYSIS (HD-SCA) OF PROSTATE CANCER (PCA) CELLS IN MATCHED BONE MARROW AND BLOOD FROM PATIENTS

7028 Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer (CRPC): analysis of Study CA180–086

1053PDFINITE ANDROGEN DEPRIVATION THERAPY (ADT) PLUS IPILIMUMAB (IPI) IN MEN WITH HORMONE-NAïVE METASTATIC PROSTATE CANCER (HN-MPCA)

Finite Androgen Deprivation Therapy (Adt) Plus Ipilimumab (Ipi) in Men with Hormone-Naïve Metastatic Prostate Cancer (Hn-Mpca)

Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer

Usefulness of the top-scoring pairs of genes for prediction of prostate cancer progression

4025 POSTER A phase I/II study of sunitinib in combination with docetaxel (dcx) and prednisone (pdn) in patients with metastatic castrate-resistant prostate cancer (mCRPC)

A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation

The Impact of Abiraterone Acetate (AA) Therapy on Patient-Reported Pain and Functional Status in Chemotherapy-Naive Patients with Progressive, Metastatic Castration-Resistant Prostate Cancer (MCRPC)

556 Abiraterone acetate improves overall survival in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Impact of crossover and baseline prognostic factors in the COU-AA-302 final analysis

97 Updated interim analysis (IA): Results of randomized phase 3 study COU-AA-302 of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy

625 THE SPECIFIC CLINICAL CHARACTERISTICS OF DUCTAL PROSTATE CANCER

Obesity, Weight Gain, and Risk of Biochemical Failure Among Prostate Cancer Patients Following Prostatectomy

Germ-cell tumor survivors: the price for cure

ACTIVE SURVEILLANCE FOR CLINICALLY LOCALIZED PROSTATE CANCER IN THE ERA OF TECHNOLOGY: INTRODUCTION OF A PROSPECTIVE PROTOCOL INTO A HIGH VOLUME TERTIARY REFERRAL CENTRE

A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final resultsof a phase III randomized trial

Pattern of Failure and Survival of Patients with Metastatic Urothelial Tumors Relapsing after Cis-Platinum-Based Chemotherapy

79 POSTER Correlative results of in-vivo monitoring of platelet-derived growth factor receptor (PDGFR) activation status in a randomized placebocontrolled trial of docetaxel +/− imatinib in castration-resistant prostate cancer (CRPC) and bone metastases (BM)

Suchergebnisse filtern